Tango Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $20.62M, a 3449.74% increase year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $17.61M, a 880150.00% increase year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $2.54M, a 5.79% increase year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $581.00K, a 55.68% decline year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $10.14M, a 70.61% increase from fiscal 2024.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $5.94M, a 206.08% increase from fiscal 2023.
- Tango Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.94M.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $20.62M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $17.61M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $10.14M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $2.54M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $581.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $5.94M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $2.40M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $1.31M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $1.26M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $1.94M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $441.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $586.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $73.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |